Psychiatry

Phthalates were particularly linked to negative behaviors in adolescents who developed ADHD.

Data shows certain personality traits are linked to a COPD patient's likelihood of active or sedentary behaviors.

Children of mothers with PCOS need additional psychological support and longer mental health follow-up.

Investigators did note that belief in statin use was weaker in patients with confirmed statin associated muscle symptoms when compared with non-SAMS patients.

A new model using proteomic data from individuals at age 12 could help predict psychotic experiences at age 18.

J. John Mann, MD, discusses potential next steps for further assessment of ketamine's antidepressant effects.

Tardive dyskinesia at treatment onset was the strongest predictor of schizophrenia relapse.

Telemedicine could be something that is still used, even after the COVID-19 pandemic is over.

Residential addiction treatment programs may not offer the best quality of care.

Approximately 50% of patients with a mTBI who experience fatigue or sleep-wake disturbances 2 weeks following the injury continue to have problems at the 3 month mark.

Investigators identify 7 themes and interventions from an analysis of studies relating to mental health and COVID-19.

An expert discusses ALKS 3831, a potential new treatment that demonstrated reduced weight gain in patients with schizophrenia compared to olanzapine.

J. John Mann, MD, discusses findings in a new study that uncovers the mechanisms behind Ketamine's antidepressant effect.

The potential new treatment has demonstrated reduced weight gain in patients with schizophrenia compared to olanzapine.

J. John Mann, MD, compares esketamine nasal spray to intravenous administration and explains the drawbacks of the newly approved treatment method for MDD.

The majority of older adults participating in the study expressed outrage at what they deemed to be an inadequate government response to the pandemic.

J. John Mann, MD, gives a brief overview of where we are now in treatment of major depressive disorder.

Genetic and environmental liability were linked to poorer mental health in a cohort of more than 6000 individuals based in the Netherlands.

Recent surveys reveal that 40.9% of 5470 respondents are suffering from adverse mental or behavioral health conditions related to the pandemic.

Low- and moderate-frequency magnetic seizure therapy help patients with treatment-resistant depression go into remission.

A number of new modifiable risk factors for depression were identified including confiding in others, time spent watching television, and daytime napping.

As every practitioner knows, it is difficult to support staff while deliberately seeing fewer patients to save one’s own soul.

According to new findings, low Glx response is associated with increase in clinical improvements in at-need patients.

The risk of depression or clinically relevant depressive symptoms did not significantly differ between a group taking Vitamin D and a group taking a placebo.

MagVenture TMS Therapy can be used as adjunctive therapy to other OCD treatments.